vTv Therapeutics (NASDAQ:VTVT) is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for diabetes, Alzheimer's disease, and other disorders. Leveraging a deep understanding of the diseases they target, vTv Therapeutics focuses on addressing the unmet medical needs of patients around the globe. Their innovative approach involves manipulating key pathways responsible for the pathological processes in these conditions. Key projects include the development of TTP399, a potential treatment for type 1 diabetes, which has shown promise in improving glycemic control without increasing the risk of hypoglycemia. Their objectives are rooted in bringing transformative therapies from the lab to the patient, aiming to improve outcomes and enhance the quality of life for those afflicted by chronic diseases.